Clinical Nutrition For Diabetes Care Market Size To Hit USD 3.69 Bn By 2033
The global clinical nutrition for diabetes care market size was estimated at USD 2.31 billion in 2023 and is projected to hit around USD 3.69 billion by 2033, growing at a CAGR of 4.79% during the forecast period from 2024 to 2033.
Key Takeaways:
Clinical Nutrition For Diabetes Care Market Growth
The increasing demand for specialized food products by individuals with diabetes or those at risk of developing the condition is a critical factor for the diabetes clinical nutrition market growth. This includes people with type 1 or type 2 diabetes, as well as those following a diabetic diet. According to the International Diabetes Federation, Europe had 61 million diabetes patients in 2021, accounting for 10.3% of men and 9.6% of women aged 25 years and over. Moreover, by 2045, 1 in 8 adults, approximately 783 million, will be living with diabetes, depicting a 46% rise from the current statistics. Moreover, over 90% of people with diabetes have type 2 diabetes, which is driven by socio-economic, demographic, environmental, and genetic factors.
The increase in the prevalence of diabetes due to aging, obesity, and unhealthy lifestyle is one of the factors contributing to the growth of the global clinical nutrition market. Obesity is a major factor leading to diabetes. According to the World Health Organization (WHO), in 2021, an estimated 39% of adults aged 18 years and over were overweight, and 13% were obese globally. According to an article published in ScienceDirect in July 2021, the prevalence of peripheral neuropathy was high among diabetic patients, accounting for around 40.3%, and type 2 diabetic patients are more susceptible to it than type 1 diabetic patients. The risk of neuropathy significantly increases with age, changes in diet, and unhealthy lifestyles. Clinical nutrition including medical foods and parenteral nutrition can help relieve symptoms or slow down the progression of a chronic condition.
A study by the University of Minnesota suggests that the incidence of type 2 diabetes increased by 62% in the U.S., following the coronavirus outbreak. Moreover, kids aged 10-19 were among those specifically affected. The COVID-19 pandemic catalyzed the shift towards different care models and paving the way for the swift introduction of novel solutions for diabetes management. As the number of people with diabetes continues to grow, so does the demand for these specialized food products. Patients afflicted with diabetes are at higher risk of comorbidities, as diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation, as reported by the WHO.
The increasing popularity of diabetes nutrition food is driven by a combination of scientific evidence, public health initiatives, and consumer demand for better health outcomes. Consumer behavior regarding diabetic care nutrition focuses on prioritizing low-sugar, low-carbohydrate, and low-calorie foods while maintaining palatability and ease of preparation. Moreover, their preference for healthier alternatives is driven by a combination of personal health concerns, taste preferences, convenience, and budget considerations. Many consumers are willing to spend more for products that are perceived as healthier, indicating a strong desire to make informed decisions about their dietary habits.
Clinical Nutrition For Diabetes Care Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 2.42 Billion |
| Market Size by 2033 | USD 3.69 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.79% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, stage, sales channel, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott Nutrition; Pfizer Inc.; Bayer AG; Nestlé Health Science S.A..; GlaxoSmithKline plc; Baxter International Inc.; Otsuka Holdings Co., Ltd.; Mead Johnson & Company, LLC; Danone Nutricia; Victus, Inc. |
Regional Insights
North America clinical nutrition for diabetes care market accounted for a share of 33.48% in 2023. The large market share in the region is driven by a strong healthcare infrastructure, favorable reimbursement policies and the presence of large clinical nutrition companies. Moreover, high public and private investment in healthcare and a shift towards wholistic treatment regimens has aided the market growth in the region.
U.S. Clinical Nutrition for Diabetes Care Market Trends
The U.S. clinical nutrition market for diabetes care dominated the North American region with approximately 87% revenue share. The market for clinical nutrition for diabetes care is expanding swiftly worldwide; however, the U.S. leads the way due to its robust healthcare system and an increasing elderly population. The country is at the forefront of technological developments, specifically in healthcare.
Europe Clinical Nutrition for Diabetes Care Market Trends
Clinical nutrition for diabetes care market in Europe was the second-largest regional market in 2023. European guidelines by the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), backed by scientific evidence to manage diabetes, stress the significance of eating plant-based foods that are minimally processed. By following evidence-based dietary recommendations and receiving individualized medical nutrition therapy (MNT), individuals with diabetes in Europe can effectively manage their condition, reduce complications, and improve their overall quality of life.
Germany clinical nutrition for diabetes care market dominated Europe a share of over 19.9% in 2023 and is anticipated to witness lucrative growth over the forecast period. Healthcare facilities in Germany are known for their high-quality treatment of complications related to diabetes. They prioritize conservative treatments as much as possible and only opt for surgical procedures such as organ transplants when absolutely necessary. Furthermore, they utilize advanced diagnostic techniques and usage of personalized nutrition, which allow for the early identification and management of complications associated with diabetes, thereby improving the prognosis for patients.
Clinical nutrition for diabetes care market in UK is the second largest in Europe, and is anticipated to witness lucrative growth. In the UK, a range of diabetes medications are available, including metformin, sulphonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. These drugs are effective in controlling blood glucose levels and averting complications. The goal of these medications is to ward off immediate complications such as hypoglycemia and hyperglycemia, while also minimizing the risk of chronic complications like cardiovascular diseases and kidney problems. These medications in combination of medical food are effective in the management of diabetes. In England, type 2 diabetes patients are exempt from paying for their medications, promoting adherence to their prescribed treatment plans due to the availability of free prescriptions. Such favorable government initiatives will further boost the country's market growth.
Asia Pacific Clinical Nutrition for Diabetes Care Market Trends
Clinical nutrition for diabetes care market in Asia Pacific is anticipated to witness lucrative CAGR of nearly 6.1% from 2024 to 2033. According to PubMed, the high incidence of diabetes in the Asia-Pacific region is a major issue, as over 60% of individuals with diabetes live in Asia, especially in nations such as China and India. With the rising prevalence of diabetes in the Asia-Pacific region, there is a growing recognition of the importance of implementing effective strategies to address these challenges including the effective nutritional management of patients suffering from diabetes.
China clinical nutrition for diabetes care market recorded the largest revenue share of over 32.7% in Asia pacific in 2023 and is expected to grow at a lucrative CAGR over the forecast period. In China, the usage of prescribed clinical nutrition varies depending on specific conditions and settings. The implementation of clinical nutrition in China is expanding, especially in the context of addressing malnutrition among the elderly. The country also implemented a National Nutritional Plan aimed towards educating the importance of dietary management from 2017 to 2033.
Clinical nutrition for diabetes care market in India is anticipated to witness the fastest growth during the forecast period. Clinical nutrition is essential in India, aiding the adoption of diets with proper glycemic control and lipid profiles. Baxter International Inc., a global leader in clinical nutrition, has led initiatives to raise awareness about the proper nutrition for diabetes in India. Furthermore, in August 2022, Bayer launched a pill to manage chronic kidney disease associated with diabetes type 2.
Japan clinical nutrition market for diabetes care is a significant part of the Asia Pacific region and is expected to see lucrative growth during the forecast period. The consensus statement on ‘Pharmacotherapy in People with Type 2 Diabetes Mellitus’ by the Japan Diabetes Society emphasizes the need to take into account factors such as the patient’s metabolic imbalance, age, obesity, insulin secretion/insulin resistance, and chronic complications when choosing antidiabetic drugs and clinical nutrition formulas.
Segments Insights:
Product Insights
Oral clinical nutrition for diabetes care dominated the market in 2023, commanding a 71.9% market share. Oral nutritional therapy is vital for diabetes management as it significantly aids in controlling blood sugar levels, supports weight regulation, and helps avoid diabetes-related complications. There is substantial evidence indicating that oral nutrition therapy is both effective and cost-efficient when integrated into a holistic approach to diabetes care.
Enteral feeding formulas in diabetes care are expected to grow at the fastest pace over the forecast period. The demand for diabetes-specific enteral feeding formulas is on the rise, driven by numerous studies that attest to their efficacy in managing diabetes patients who need enteral nutrition. When compared to standard formulas, DSFs have shown superior performance in regulating HbA1c and insulin response in diabetes patients on enteral feed. Therefore, the adoption of diabetes-specific enteral feeding formulas presents benefits in terms of blood sugar control and comprehensive care for diabetes patients who require enteral nutrition.
Stage Insights
Adults segment led the diabetes clinical nutrition market with a share of over 85.11% in 2023, owing to the increasing prevalence of nutritional deficiency and malnutrition among the adult population. Adult age group are more prone to the reduced muscle strength, vitamins, and calcium deficiency among the women population of age group above 30 years, apathy, lower immunity, hypertension, and fatigue. This leads to the nutritional deficiency among the adult population. According to the OECD, India, Sri Lanka, Pakistan, and Bangladesh are prominent contributors to the global burden.
The adults segment is also anticipated to grow the fastest over the forecast period. Globally, the total cases of diabetes in adults has seen a rise due to growing urbanization, sedentary lifestyles, and unhealthy eating habits. Physical inactivity is a popular trend seen in the adult population and contributes to poor blood sugar control, weight gain, and insulin resistance. The rise in geriatric population is also a major factor contributing to segment growth.
Sales Channel Insights
The institutional sales segment dominated the market with over 40.12% revenue share in 2023. The sales channel includes commercial sales to the government organizations, hospitals, and research institutes. The rising prevalence of the diseases and advancements in the hospital care leads to the rise in the patient visits to the hospitals which drives the segment. Moreover, as patient awareness rises, the tendency to use official hospital channels for obtaining diabetes care nutrition prescriptions has also seen a growth.
The online sales segment is anticipated to witness fastest growth over the forecast period. The progress in telemedicine and ePharmacy has facilitated global distribution of clinical nutrition products, enabling manufacturers to expand their reach and cater to underrepresented communities. Hence, there is an increase in the online sales due to the rising customer demand for diabetes care supplements via online platforms and stores.
Recent Developments
Key Clinical Nutrition for Diabetes Care Companies:
The following are the leading companies in the clinical nutrition for diabetes care market. These companies collectively hold the largest market share and dictate industry trends.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Clinical Nutrition For Diabetes Care market.
By Product
By Stage
By Sales Channel
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Stage
1.2.3. Sales Channel
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Stage Outlook
2.2.3. Sales Channel Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
Chapter 3. Global Clinical Nutrition for Diabetes Care Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.3. Market opportunity analysis
3.3. Global Clinical Nutrition for Diabetes Care Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Global Clinical Nutrition for Diabetes Care Market: Product Estimates & Trend Analysis
4.1. Global Clinical Nutrition for Diabetes Care Market: Product Dashboard
4.2. Global Clinical Nutrition for Diabetes Care Market: Product Movement Analysis
4.3. Global Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4. Oral Nutrition
4.4.1. Market estimates and forecasts 2020 to 2033
4.5. Parenteral Nutrition
4.5.1. Market estimates and forecasts 2020 to 2033
4.6. Enteral Feeding Formulas
4.6.1. Market estimates and forecasts 2020 to 2033
Chapter 5. Clinical Nutrition for Diabetes Care Market: Stage Estimates & Trend Analysis
5.1. Clinical Nutrition for Diabetes Care Market: Stage Dashboard
5.2. Clinical Nutrition for Diabetes Care Market: Stage Movement Analysis
5.3. Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4. Adult
5.4.1. Market estimates and forecasts 2020 to 2033
5.5. Pediatric
5.5.1. Market estimates and forecasts 2020 to 2033
Chapter 6. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Estimates & Trend Analysis
6.1. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Dashboard
6.2. Global Clinical Nutrition for Diabetes Care Market: Sales Channel Movement Analysis
6.3. Global Clinical Nutrition for Diabetes Care Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4. Online
6.4.1. Market estimates and forecasts 2020 to 2033
6.5. Retail
6.5.1. Market estimates and forecasts 2020 to 2033
6.6. Institutional Sales
6.6.1. Market estimates and forecasts 2020 to 2033
Chapter 7. Global Clinical Nutrition for Diabetes Care Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2020 to 2033
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2020 to 2033
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2020 to 2033
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2020 to 2033
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2020 to 2033
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2020 to 2033
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2020 to 2033
7.6.6. Denmark
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Denmark market estimates and forecasts 2020 to 2033
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2020 to 2033
7.6.8. Norway
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Norway market estimates and forecasts 2020 to 2033
7.7. Asia Pacific
7.7.1. China
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. China market estimates and forecasts 2020 to 2033
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2020 to 2033
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2020 to 2033
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2020 to 2033
7.7.5. Thailand
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. Thailand market estimates and forecasts 2020 to 2033
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2020 to 2033
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2020 to 2033
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2020 to 2033
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2020 to 2033
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2020 to 2033
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2020 to 2033
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2020 to 2033
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2020 to 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Abbott Nutrition
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Pfizer Inc.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Bayer AG
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Nestle Health Science S.A.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. GlaxoSmithKline plc
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Baxter International Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Otsuka Holdings Co., Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Mead Johnson & Company, LLC
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Danone Nutricia,
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Victus, Inc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers